title: [Use of low molecular weight heparin for medical prophylaxis by European geriatricians].
abstract: OBJECTIVE
  Many hospitalised elderly patients are at increased risk of venous thromboembolism (VTE). The aim of this study was to assess the rate and duration of medical utilization of low molecular weight heparin (LMWH) for VTE prevention by European geriatricians.
  
  
  METHODS
  A questionnaire was sent to 94 geriatricians of the European Academy for Medicine of Ageing (EAMA), to be filled out for each patient older than 65 years of their institutions who received LMWH during 1 day of December 2000.
  
  
  RESULTS
  In the 37 centers that participated (representing 11 different European countries) 2912 patients were present on the day of the study: 857 patients in acute care, 367 in rehabilitation care, 1568 in long-term care and 141 in day hospital. Prophylaxis by LMWH was given to 284 medical patients (9.75%, mean age 82.2 years). Use of LMWH was more frequent in acute and rehabilitation care (22.4% and 9.8%) than in long-term care (3.1%). The main risk factors in patients with LMWH prophylaxis were: bedridden (53%), infectious disease (18%), heart failure (17.6%), venous insufficiency (17.6%), paralysis of lower limbs (16.6%), recent stroke (15%) and malignancy (10%). The duration of the treatment for VTE prophylaxis exceeded 30 days in 51 patients (12%) and one year in 15 patients (3.3%).
  
  
  CONCLUSIONS
  In Europe, VTE prophylaxis by LMWH is widely used in elderly medical patients without specific guidelines in this population. Further studies are necessary to evaluate the appropriate duration of prophylaxis in very prolonged immobilization.
authors.affiliation: Service de gérontologie et de soins palliatifs, hôpital Paul-Brousse, 14, avenue Paul-Vaillant-Couturier 94800 Villejuif cedex, France. christophe.trivalle@pbr.ap-hop-paris.fr
authors.forename: C
authors.initials: C
authors.lastname: Trivalle
authors.forename: G
authors.initials: G
authors.lastname: Ongaro
mesh_terms: D000368:Aged; D000925:Anticoagulants / Q000627:therapeutic use*; D005060:Europe; D005602:France; D005853:Geriatrics / Q000639:trends*; D006495:Heparin, Low-Molecular-Weight / Q000627:therapeutic use*; D006707:Homes for the Aged; D006801:Humans; D007297:Inpatients; D008134:Long-Term Care; D011795:Surveys and Questionnaires; D013923:Thromboembolism / Q000517:prevention & control*
chemical_list: D000925:Anticoagulants; D006495:Heparin, Low-Molecular-Weight